Promega Corporation

University of Utah Research Foundation

Andrew S Dixon

Keith V Wood

Lance P Encell

Monika G Wood

Thomas Machleidt

Marie Schwinn

Thomas A Kirkland

Mary P Hall

Poncho Meisenheimer

Brock Binkowski

Matthew B Robers

Said A Goueli

James Unch

Melanie Dart

Nidhi Nath

Hicham Zegzouti

Subhanjan Mondal

Dileep K Pulukkunat

Shawn Owen

Kris Zimmerman

Benjamin J Bruno

Carol S Lim

Geoffrey D Miller

Julio C Delgado

Brock F Binkowski

Keith Wood

Mary Hall

Thomas Kirkland

Matthew Robers

Said Goueli

Monika Wood

Lance Encell

Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.

Activation of bioluminescence by structural complementation

Split enzyme reporter systems are disclosed for detecting an analyte in a mixture. Fragments of the split enzyme may be covalently bound to targeting domains that bind to target regions of an analyte, thereby causing formation of an active complex. Some split enzyme reporter systems can be used to detect an analyte without the use of analyte immobilization, blocking, or wash steps. Some reporter systems also enable rapid detection of the analyte of interest.

Target-binding activated split reporter systems for analyte detection and related components and methods

Activation of bioluminescene by structural complementation

Provided herein are substantially non-luminescent peptide/polypeptide tags that are inserted internally within a protein of interest or between N-terminal and C-terminal peptides/polypeptides. Interaction of the internally-inserted tag with a complement polypeptide/peptide that is also substantially non-luminescent results in the formation a bioluminescent reporter complex.

Internal protein tags

In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Peptide inhibitors of BCR-ABL oligomerization

Growing community of inventors

Verona, WI, United States of America

Andrew S Dixon